JAK1
ENSG00000162434
Target class
Kinase
Chromosome
1
Approved drugs
11
Clinical candidates (approved and in development)
23
- Approved drugs
- 11
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 23
- Chemical probe available
- Yes
- Target name
- JAK1
- Gene name
- Janus kinase 1
- Gene symbol
- JAK1
- Previous gene symbols
- JAK1B
- Protein name
- Tyrosine-protein kinase JAK1 (EC 2.7.10.2) (Janus kinase 1) (JAK-1)
- JAK1A
- JTK3
- Gene biotype
- Protein coding
- Gene family
- FERM domain containing|Jak family tyrosine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Highest tissue expression
- 139.9
- Tissue specificity (Gini)
- 0.292
- Tissue specificity (tau)
- 0.586
- KEGG gene identifiers
- hsa:3716
- Protein interaction confidence
- 0.892741
- Protein interaction partners
- 147
- R-HSA-1059683
- R-HSA-110056
- R-HSA-112411
- R-HSA-1169408
- R-HSA-1266695
- R-HSA-449836
- R-HSA-5673001
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-6788467
- R-HSA-877300
- R-HSA-877312
- R-HSA-8854691
- R-HSA-8983432
- R-HSA-8984722
- R-HSA-8985947
- R-HSA-9020558
- R-HSA-9020591
- R-HSA-9020956
- R-HSA-9020958
- R-HSA-909733
- R-HSA-912526
- R-HSA-912694
- R-HSA-9674555
- R-HSA-9679191
And 6 more, listed on the interactive page.
- End position
- 65067754
- Start position
- 64833223
- Chromosome
- 1
- Strand
- Reverse
- Endomembrane system
- Peripheral membrane protein. Note=Wholly intracellular, possibly membrane associated.
- Tissue specificity (tau)
- 0.586133
- Expression inequality (Gini)
- 0.291699
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 139.9
- Adipose - Subcutaneous
- 124.01
- Lung
- 110.05
- Cervix - Endocervix
- 107.29
- Ovary
- 101.36
Expression in transcripts per million
- Cells - Cultured fibroblasts139.9
- Adipose - Subcutaneous124.01
- Lung110.05
- Cervix - Endocervix107.29
- Ovary101.36
- Adipose - Visceral (Omentum)98.95
- Artery - Tibial97.39
- Breast - Mammary Tissue97.3
- Cervix - Ectocervix95.4
- Spleen95.08
- Uterus90.81
- Skin - Sun Exposed (Lower leg)83.99
- Fallopian Tube83
- Bladder82.83
- Artery - Coronary76.18
- Thyroid75.52
- Artery - Aorta74.51
- Vagina71.7
- Small Intestine - Terminal Ileum71
- Skin - Not Sun Exposed (Suprapubic)69.94
- Nerve - Tibial68.79
- Esophagus - Gastroesophageal Junction66.76
- Colon - Sigmoid66.4
- Brain - Cerebellar Hemisphere65.69
- Esophagus - Muscularis64.69
And 29 more, listed on the interactive page.
- GO:0006468
- GO:0007259
- GO:0019221
- GO:0034112
- GO:0035556
- GO:0035723
- GO:0035771
- GO:0038110
- GO:0038111
- GO:0038113
- GO:0038154
- GO:0038165
- GO:0046677
- GO:0048861
- GO:0060333
- GO:0060337
- GO:0070102
- GO:0070120
- GO:0072540
- GO:0140105
- GO:0150105
- GO:1900182
- GO:1903672
- GO:0005634
- GO:0005737
- GO:0005768
- GO:0005788
- GO:0005829
- GO:0005886
- GO:0005925
- GO:0009898
- GO:0031234
- GO:0004713
- GO:0004715
- GO:0005515
- GO:0019903
- GO:0031625
Related records
Trials (1,162)
- "Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.
- 3T Therapy in the Treatment of MDA5-positive Dermatomyositis
- A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
- A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
- A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
- A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
- A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
- A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
- A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
- A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
- A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
- A Hepatic Impairment Study for PF-04965842.
Drugs (26)
- Abrocitinib Tyrosine-protein kinase JAK1 inhibitor
- Baricitinib Tyrosine-protein kinase JAK1 inhibitor
- Brepocitinib Tyrosine-protein kinase JAK1 inhibitor
- Cerdulatinib Tyrosine-protein kinase JAK1 inhibitor
- Delgocitinib Janus Kinase (JAK) inhibitor
- Deuruxolitinib phosphate Tyrosine-protein kinase JAK1 inhibitor
- Filgotinib Tyrosine-protein kinase JAK1 inhibitor
- Filgotinib maleate Tyrosine-protein kinase JAK1 inhibitor
- GLPG-0555 Tyrosine-protein kinase JAK1 inhibitor
- Golidocitinib Tyrosine-protein kinase JAK1 inhibitor
- Gusacitinib Janus Kinase (JAK) inhibitor
- INCB-047986 Tyrosine-protein kinase JAK1 inhibitor
- Itacitinib Tyrosine-protein kinase JAK1 inhibitor
- Izencitinib Janus Kinase (JAK) inhibitor
- Momelotinib Tyrosine-protein kinase JAK1 inhibitor
- Momelotinib dihydrochloride monohydrate Tyrosine-protein kinase JAK1 inhibitor
- Nezulcitinib Janus Kinase (JAK) inhibitor
- Peficitinib Janus Kinase (JAK) inhibitor
- Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor
- Ruxolitinib phosphate Tyrosine-protein kinase JAK1 inhibitor